Search results
-
ASCO 2024 – J&J flies towards a more convenient Rybrevant
ASCO 2024 – J&J flies towards a more convenient Rybrevant … non-inferiority criteria; **trend in favour of SC. Source: ASCO 2024. When asked for a potential explanation …
- 05/19/2026 - 19:49 -
ASCO 2024 – Scemblix could set new standard in front-line leukaemia
ASCO 2024 – Scemblix could set new standard in front-line …
- 05/19/2026 - 19:49 -
ASCO 2024 preview – conjugates in focus
ASCO 2024 preview – conjugates in focus … molecules. Selected ADCs being presented at ASCO 2024 Project Target Payload Company …
- 05/19/2026 - 19:49 -
ASCO 2024 preview – with more patients Merus claims better efficacy
ASCO 2024 preview – with more patients Merus claims better …
- 05/19/2026 - 19:49 -
Verastem spoils its ASCO bounce
… patients as well as those with KRAS-mutant disease. ASCO 2024 In mid-2020 Verastem bought avutometinib, a …
- 05/19/2026 - 19:49 -
ASCO 2024 abstract movers – Merus convinces, at first
ASCO 2024 abstract movers – Merus convinces, at first …
- 05/19/2026 - 19:49 -
ASCO 2024 preview – toxicity looms large for J&J
ASCO 2024 preview – toxicity looms large for J&J …
- 05/19/2026 - 19:49 -
ASCO 2024 preview – more questions for BioNTech
ASCO 2024 preview – more questions for BioNTech … 33% Note: cutoff date 9 January 2024. Source: ASCO 2024 abstract. This could come at a cost, … 63% Note: cutoff date 20 December 2023. Source: ASCO 2024 abstract. In the second line, results …
- 05/19/2026 - 19:49 -
ASCO 2024 preview – Merus’s home run remains unconfirmed
ASCO 2024 preview – Merus’s home run remains unconfirmed …
- 05/19/2026 - 19:49 -
ASCO 2024 preview – waiting for Blueprint and Caribou
ASCO 2024 preview – waiting for Blueprint and Caribou …
- 05/19/2026 - 19:49
